Consolidation of molecular testing in clinical virology

References

• Chernesky MA. An evolutionary change in diagnostic virology. Yale J Biol Med. 1989;62(2):89–92.
   PubMed Web of Science ®Google Scholar
• Scott JM, Simon CE. The diagnosis of smallpox by the Paul method. Am J Epidemiol. 1923;3(4):401–415.
   Google Scholar
• Fairbrother RW. Handbook of filterable viruses. London: William Heinemann Ltd; 1934.
   Google Scholar
• Ivanovsky D. Concerning the mosaic disease of the tobacco plant. St Petsb Acad Imp Sci Bul. 1882;35:67–70.
   Google Scholar
• Ivanovsky D. On the mosaic disease of tobacco. Z Pflanzenkr Pflanzenpathol Pflanzenschutz. 1903;13:1–41.
   Google Scholar
• Beierinck MW. Concerning a contagium vivum fluidum as a cause of the spot-disease of tobacco leaves. Verh Akad Wet. 1898;6:3–21.
   Google Scholar
• Enquist LW. Virology in the 21st century. J Virol. 2009;83(11):5296–5308.
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359–362.
   PubMed Web of Science ®Google Scholar
• Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871.
   PubMed Web of Science ®Google Scholar
• Bedson SP, Bland JOW. Complement-fixation with filtrable viruses and their antisera. Br J Exp Pathol. 1929;10(6):393–404.
   Google Scholar
• Goldsmith CS, Miller SE. Modern uses of electron microscopy for detection of viruses. Clin Microbiol Rev. 2009;22(4):552–563.
   PubMed Web of Science ®Google Scholar
• Weller TH, Robbins FC, Enders JF. Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proc Soc Exp Biol Med. 1949;72(1):153–155.
   PubMed Web of Science ®Google Scholar
• Enders JF, Weller TH, Robbins FC. Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109(2822):85–87.
   PubMed Web of Science ®Google Scholar
• Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci U S A. 1952;38(8):747–752.
   PubMed Web of Science ®Google Scholar
• McQuillin J, Gardner PS. Rapid diagnosis of respiratory syncytial virus infection by immunofluorescent antibody techniques. Br Med J. 1968;1(5592):602–605.
   PubMed Web of Science ®Google Scholar
• Hers JF, Van Der Kuip L, Masurel N. Rapid diagnosis of influenza. Lancet. 1968;1(7541):510–511.
   PubMed Web of Science ®Google Scholar
• Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry. 1971;8:871–874.
   PubMedGoogle Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497.
   PubMed Web of Science ®Google Scholar
• Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463–5467.
   PubMed Web of Science ®Google Scholar
• Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230(4732):1350–1354.
   PubMed Web of Science ®Google Scholar
• Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. 1987;155:335–350.
   PubMed Web of Science ®Google Scholar
• Higuchi R, Fockler C, Dollinger G, et al. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y). 1993;11(9):1026–1030.
   PubMedGoogle Scholar
• Kacian DL, Fultz TJ Nucleic acid sequence amplification methods. US Patent No 5399491. 1995.
   Google Scholar
• Candotti D, Richetin A, Cant B, et al. Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion. 2003;43(2):215–225.
   PubMed Web of Science ®Google Scholar
• Hodinka RL. The clinical utility of viral quantitation using molecular methods. Clin Diagn Virol. 1998;10(1):25–47.
   PubMedGoogle Scholar
• Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 1987;327(6122):473–476.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236–9241.
   PubMed Web of Science ®Google Scholar
• Swenson PD, El-Sabaeny A, Thomas-Moricz V, et al. Evaluation of a transcription mediated amplification assay for detection of herpes simplex virus types 1 and 2 mRNA in clinical specimens. J Clin Virol. 2016 Jul;80:62–67.
   PubMed Web of Science ®Google Scholar
• Faddy HM, Flower RL, Seed CR, et al. Detection of emergent strains of West Nile virus with a blood screening assay. Transfusion. 2016;56(6 Pt 2):1503–1507.
   PubMed Web of Science ®Google Scholar
• Barba M, Czosnek H, Hadidi A. Historical perspective, development and applications of next-generation sequencing in plant virology. Viruses. 2014;6(1):106–136.
   PubMed Web of Science ®Google Scholar
• Briese T, Kapoor A, Mishra N, et al. Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis. mBio. 2015;6(5):e01491–15.
   PubMed Web of Science ®Google Scholar
• Weidemaier K, Carrino J, Curry A, et al. Advancing rapid point-of-care viral diagnostics to a clinical setting. Future Virology. 2015;10(3):313–328.
   Web of Science ®Google Scholar
• Briedigkeit L, Müller-Plathe O, Schlebusch H, et al. Patientennahe laboratoriumsdiagnostik (point-of-care-testing). J Lab Med. 1998;22:414–420.
   Google Scholar
• Haleyur Giri Setty MK, Hewlett IK. Point of care technologies for HIV. AIDS Res Treat. 2014;2014:497046.
   PubMedGoogle Scholar
• Li-Kim-Moy J, Dastouri F, Rashid H, et al. Utility of early influenza diagnosis through point-of-care testing in children presenting to an emergency department. J Paediatr Child Health. 2016;52(4):422–429.
   PubMed Web of Science ®Google Scholar
• Johannessen A. Where we are with point-of-care testing. J Viral Hepat. 2015;22(4):362–365.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Khuroo NS, Khuroo MS. Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis. PLoS One. 2015;10(3):e0121450.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Tiwari S, Dev Jayant R, et al. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron. 2016;75:254–272.
   PubMed Web of Science ®Google Scholar
• Sankar S, Ramamurthy M, Nandagopal B, et al. Molecular and nanotechnologic approaches to etiologic diagnosis of infectious syndromes. Mol Diagn Ther. 2011 Jun 1;15(3):145–158.
   PubMed Web of Science ®Google Scholar
• Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of biofire filmarray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol. 2016 Sep;54(9):2251–2261.
   PubMed Web of Science ®Google Scholar
• Babady NE. The FilmArray® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn. 2013;13(8):779–788.
   PubMed Web of Science ®Google Scholar
• Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984;224(4648):497–500.
   PubMed Web of Science ®Google Scholar
• Dioverti MV, Razonable RR. Clinical utility of cytomegalovirus viral load in solid organ transplant recipients. Curr Opin Infect Dis. 2015;28(4):317–322.
   PubMed Web of Science ®Google Scholar
• Vora SB, Englund JA. Cytomegalovirus in immunocompromised children. Curr Opin Infect Dis. 2015;28(4):323–329.
   PubMed Web of Science ®Google Scholar
• Yip TT, Ngan RK, Fong AH, et al. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014;50(6):527–538.
   PubMed Web of Science ®Google Scholar
• Ruf S, Wagner HJ. Determining EBV load: current best practice and future requirements. Expert Rev Clin Immunol. 2013;9(2):139–151.
   PubMed Web of Science ®Google Scholar
• Wiesmann F, Braun P. Significance of HCV RNA monitoring in the era of new potent therapies. Expert Rev Anti Infect Ther. 2016;14(9):837–844.
   PubMed Web of Science ®Google Scholar
• De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–1207.
   PubMed Web of Science ®Google Scholar
• Utokaparch S, Marchant D, Gosselink JV, et al. The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr Infect Dis J. 2011;30:e18–23.
   PubMed Web of Science ®Google Scholar
• Jansen RR, Schinkel J, Dek I, et al. Quantitation of respiratory viruses in relation to clinical course in children with acute respiratory tract infections. Pediatr Infect Dis J. 2010;29:82–84.
   PubMed Web of Science ®Google Scholar
• Launes C, Garcia-Garcia JJ, Jordan I, et al. Viral load at diagnosis and influenza A H1N1 (2009) disease severity in children. Influenza Other Respir Viruses. 2012;6(6):e89–92.
   Google Scholar
• Scagnolari C1, Midulla F, Selvaggi C, et al. Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. Med Microbiol Immunol. 2012;201(3):311–317.
   PubMed Web of Science ®Google Scholar
• Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37:1030–1034.
   PubMed Web of Science ®Google Scholar
• Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case–control study. Lancet. 2000;355:2194–2198.
   PubMed Web of Science ®Google Scholar
• Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case–control study. Lancet. 2000;355:2189–2193.
   PubMed Web of Science ®Google Scholar
• Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004;112:854–859.
   PubMed Web of Science ®Google Scholar
• Cheung JL, Lo KW, Cheung TH, et al. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis. 2006;194:1706–1712.
   PubMed Web of Science ®Google Scholar
• Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer. 2005;92:2195–2200.
   PubMed Web of Science ®Google Scholar
• Molano M, Van Den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486–494.
   PubMed Web of Science ®Google Scholar
• Kulmala SM, Shabalova IP, Petrovitchev N, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:17–22.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167–1170.
   PubMed Web of Science ®Google Scholar
• Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS. 1996 Dec;10(Suppl 3):S1–11.
   PubMed Web of Science ®Google Scholar
• Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312(4):410–425. 30.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Deeks SG, Plasma HIV-1. RNA levels during antiretroviral therapy: how low is low enough? Clin Infect Dis. 2012;1(545):733–735.
   Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817–829.
   PubMed Web of Science ®Google Scholar
• Young J, Rickenbach M, Calmy A, et al. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect Dis. 2015;15:382.
   PubMed Web of Science ®Google Scholar
• Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia (‘blips’) in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035–2041.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171–179.
   PubMed Web of Science ®Google Scholar
• Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 2005;33:75–78.
   PubMed Web of Science ®Google Scholar
• Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016;71:1051–1055.
   PubMed Web of Science ®Google Scholar
• Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–4536.
   PubMed Web of Science ®Google Scholar
• Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879–3884.
   PubMed Web of Science ®Google Scholar
• Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol. 2009;83:8470–8481.
   PubMed Web of Science ®Google Scholar
• Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008;105:16725–16730.
   PubMed Web of Science ®Google Scholar
• Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54(5):724–732.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Galli L, Salpietro S, et al. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clin Microbiol Infect. 2013;19:E542–4.
   PubMed Web of Science ®Google Scholar
• Hofstra LM, Mudrikova T, Stam AJ, et al. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS One. 2014;9(10):e110749.
   Google Scholar
• Mexas AM, Graf EH, Pace MJ, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS. 2012;26:2295–2306.
   PubMed Web of Science ®Google Scholar
• Falasca F, Mazzuti L, dʼEttorre G, et al. Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen. J Acquir Immune Defic Syndr. 2015;68(2):e18–20.
   Google Scholar
• Arenas-Pinto A, Milinkovic A, Peppa D, et al. Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. BMC Infect Dis. 2015 Mar;21(15):138.
   Web of Science ®Google Scholar
• Boyd A, Meynard JL, Morand-Joubert L. Collaboration in HIV, inflammation and cardiovascular disease study. Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection. PLoS One. 2014;9:e113876. DOI:10.1371/journal.pone.0113876
   Google Scholar
• Estébanez M, Stella-Ascariz N, Mingorance J, et al. Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. BMC Infect Dis. 2014;14:379.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Bransom BM, Own SM, Wesolowski LG, et al. Laboratory testing for diagnosis of HIV infection: updated recommendations. 2014. Available from: www.cdc.gov/hiv/pdf/hivtestingalgorithmrecommendation-final.pdf
   Google Scholar
• Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect. 2011;17(2):116–121.
   PubMed Web of Science ®Google Scholar
• Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535–542.
   PubMed Web of Science ®Google Scholar
• Ho DD1, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123–126.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188–191.
   PubMed Web of Science ®Google Scholar
• Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver. 2002;22(2):121–126.
   PubMedGoogle Scholar
• Zeuzem S, Schmidt JM, Lee JH, et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology. 1996;23(2):366–371.
   PubMed Web of Science ®Google Scholar
• Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997;26(1):226–231.
   PubMed Web of Science ®Google Scholar
• Antonelli G, Riva E, Maggi F, et al. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha. J Infect Dis. 1999 Oct;180(4):1411–1412.
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Monteleone K, Cacciotti G, et al. Role of interferons in chronic hepatitis C infection. Curr Drug Targets. 2016;17:1-1.
   Google Scholar
• Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, et al. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother. 2012;67(1):202–205.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol. 2011;55(5):980–988.
   PubMed Web of Science ®Google Scholar
• Lindh M, Lagging M, Arnholm B, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat. 2011;18(7):e325–31.
   PubMed Web of Science ®Google Scholar
• Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593–1601.
   PubMed Web of Science ®Google Scholar
• Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30(9):1259–1269.
   PubMed Web of Science ®Google Scholar
• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385(9973):1124–1135.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Guedj J. Modelling hepatitis C therapy–predicting effects of treatment. Nat Rev Gastroenterol Hepatol. 2015;12(8):437–445.
   PubMed Web of Science ®Google Scholar
• Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther. 2014;19(2):211–220.
   PubMed Web of Science ®Google Scholar
• Adiwijaya BS, Hare B, Caron PR, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther. 2009;14(4):591–595.
   PubMed Web of Science ®Google Scholar
• Guedj J, Dahari H, Shudo E, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology. 2012 Apr;55(4):1030–1037.
   PubMed Web of Science ®Google Scholar
• Rong L, Guedj J, Dahari H, et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol. 2013;9(3):e1002959.
   Google Scholar
• Farley S. A double whammy for hep C. Nat Rev Drug Discov. 2003;2:419.
   Web of Science ®Google Scholar
• Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700–1704.
   PubMed Web of Science ®Google Scholar
• CDC. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR. 2013;62(18):362–365.
   Web of Science ®Google Scholar
• Gatselis NK, Zachou K, Saitis A, et al. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol. 2014;20(11):2839–2853.
   PubMed Web of Science ®Google Scholar
• Sarrazin C(1). The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504. 26.
   PubMed Web of Science ®Google Scholar
• Andriulli A(1), Morisco F, Ippolito AM, et al. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int. 2015 Jan;9(1):52–57.
   PubMed Web of Science ®Google Scholar
• Wyles DL(1), Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014 Apr;21(4):229–240.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015Apr;116:10–16. DOI:10.1016/j.antiviral.2015.01.003
   PubMed Web of Science ®Google Scholar
• Poveda E, Wyles DL, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014 Aug;108:181–191.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
   PubMed Web of Science ®Google Scholar
• Castle PE. The evolving definition of carcinogenic human papillomavirus. Infect Agent Cancer. 2009;11:4–7.
   Google Scholar
• Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for cervical dysplasia. J Natl Cancer Inst. 1995;87:1365–1371.
   PubMed Web of Science ®Google Scholar
• Snijders PJ, Steenbergen RD, Heideman DA, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208(2):152–164.
   PubMed Web of Science ®Google Scholar
• Ovestad IT, Gudlauqsson E, Skaland I, et al. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol. 2010;23(9):1231–1240.
   PubMed Web of Science ®Google Scholar
• Luhn P, Wentzensen N. HPV-based tests for cervical cancer screening and management of cervical disease. Curr Obstet Gynecol Rep. 2013;2:76–85.
   PubMedGoogle Scholar
• Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–532.
   PubMed Web of Science ®Google Scholar
• Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev. 2010;19:832–837.
   PubMed Web of Science ®Google Scholar
• Depuydt CE, Criel AM, Benoy IH, et al. Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cellular Mol Med. 2012;16:3096–3104.
   PubMed Web of Science ®Google Scholar
• Burger EA, Kornør H, Klemp M, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;120(3):430–438.
   PubMed Web of Science ®Google Scholar
• Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120:89–93.
   PubMed Web of Science ®Google Scholar
• Verdoodt F, Szarewski A, Halfon P, et al. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013;121:675–687.
   PubMed Web of Science ®Google Scholar
• Hudelist G, Manavi M, Pischinger KI, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol. 2004;92:873–880.
   PubMed Web of Science ®Google Scholar
• Manawapat A, Stubenrauch F, Russ R, et al. Physical state and viral load as predictive biomarkers for persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. Am J Cancer Res. 2012;2:192–203.
   PubMed Web of Science ®Google Scholar
• Marongiu L, Godi A, Parry JV, et al. Human papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer. 2014;14:384.
   PubMed Web of Science ®Google Scholar
• Leonard SM, Pereira M, Roberts S, et al. Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women. Sci Rep. 2016;6:20847.
   PubMed Web of Science ®Google Scholar
• Mulvany NJ, Allen DG, Wilson SM. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology. 2008;40:335–344.
   PubMed Web of Science ®Google Scholar
• Uijterwaal MH, Polman NJ, Witte BI, et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer. 2015;136:2361–2368.
   PubMed Web of Science ®Google Scholar
• Leonard SM(1), Wei W, Collins SI. Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis. 2012;7:1286–1293.
   Web of Science ®Google Scholar
• Pett MR, Alazawi WO, Roberts I. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 2004;64:1359–1368.
   PubMed Web of Science ®Google Scholar
• Deftereos G, Corrie SR, Feng Q, et al. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cancer. PLoS One. 2011;6:e28423.
   PubMed Web of Science ®Google Scholar
• Kudela E, Holubekova V, Farkasova A, et al. Determination of malignant potential of cervical intraepithelial neoplasia. Tumour Biol. 2016;37:1521–1525.
   PubMed Web of Science ®Google Scholar
• Song K, Nimse SB, An H, et al. HPV genotyping 9G membrane test: a point-of-care diagnostic platform. Sensors (Basel). 2014;14:19162–19175.
   PubMed Web of Science ®Google Scholar
• Pierangeli A, Gentile M, Di Marco P, et al. Detection and typing by molecular techniques of respiratory viruses in children hospitalized for acute respiratory infection in Rome, Italy. J Med Virol. 2007;79(4):463–468.
   PubMed Web of Science ®Google Scholar
• Zumla A, Al-Tawfiq JA, Enne VI, et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections–needs, advances, and future prospects. Lancet Infect Dis. 2014;14(11):1123–1135.
   PubMed Web of Science ®Google Scholar
• Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis. 2011 May;52(Suppl 4):S326–30. DOI:10.1093/cid/cir047
   PubMed Web of Science ®Google Scholar
• Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000;19:113–117.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191:1861–1868.
   PubMed Web of Science ®Google Scholar
• Fodha I, Vabret A, Ghedira L, et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J Med Virol. 2007;79:1951–1958.
   PubMed Web of Science ®Google Scholar
• Martin ET, Kuypers J, Heugel J, et al. Clinical disease and viral load in children infected with respiratory syncytial virus or human metapneumovirus. Diagn Microbiol Infect Dis. 2008;62:382–388.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Jartti T, Mansbach JIM, et al. Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. J Infect Dis. 2015;211:1550–1559.
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011;204:996–1002.
   PubMed Web of Science ®Google Scholar
• Skjerven HO, Megremis S, Papadopoulos NG, et al. Virus type and genomic load in acute bronchiolitis: severity and treatment response with inhaled adrenaline. J Infect Dis. 2016;213(6):915–921.
   PubMed Web of Science ®Google Scholar
• Nenna R, Ferrara M, Nicolai A, et al. Viral load in infants hospitalized for respiratory syncytial virus bronchiolitis correlates with recurrent wheezing at thirty-six-month follow-up. Pediatr Infect Dis J. 2015;34(10):1131–1132.
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130:91–100.e3.
   PubMed Web of Science ®Google Scholar
• Legg JP, Hussain IR, Warner JA, et al. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168:633–639.
   PubMed Web of Science ®Google Scholar
• Wright PF, Gruber WC, Peters M, et al. Illness severity, viral shedding and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis. 2002;185:1011–1018.
   PubMed Web of Science ®Google Scholar
• Bennett BL, Garofalo RP, Crou SG, et al. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis. 2007;195:1532–1540.
   PubMed Web of Science ®Google Scholar
• Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102:1114–1120.
   PubMed Web of Science ®Google Scholar
• Schilham MW, Claas EC, Van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis. 2002;35:526–532.
   PubMed Web of Science ®Google Scholar
• Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002;100:2005–2011.
   PubMed Web of Science ®Google Scholar
• Ishizaki Y, Tezuka J, Ohga S, et al. Quantification of circulating varicella zoster virus-DNA for the early diagnosis of visceral varicella. J Infect. 2003;47(2):133–138.
   PubMed Web of Science ®Google Scholar
• Segovia JC, Guenechea G, Gallego JM, et al. Parvovirus infection suppresses long-term repopulating hematopoietic stem cells. J Virol. 2003;77:8495–8503.
   PubMed Web of Science ®Google Scholar
• Larsson S, Soderberg-Naucler C, Wang FZ, et al. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion. 1998;38:271–278.
   PubMed Web of Science ®Google Scholar
• Schreckenberger PC, McAdam AJ Point-counterpoint: large multiplex pcr panels should be first-line tests for detection of respiratory and intestinal pathogens. J Clin Microbiol. 2015;53(10):3110–3115.
   PubMed Web of Science ®Google Scholar
• Peeling RW, McNerney R. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings. Expert Rev Mol Diagn. 2014;14(5):525–534.
   PubMed Web of Science ®Google Scholar